Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
4.65
Dollar change
-0.26
Percentage change
-5.30
%
IndexRUT P/E- EPS (ttm)-1.35 Insider Own0.74% Shs Outstand41.85M Perf Week0.00%
Market Cap194.60M Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float41.54M Perf Month-3.53%
Income-50.90M PEG- EPS next Q-0.43 Inst Own33.67% Short Float6.20% Perf Quarter-22.50%
Sales28.01M P/S6.95 EPS this Y-15.35% Inst Trans-5.54% Short Ratio12.00 Perf Half Y-6.63%
Book/sh1.17 P/B3.99 EPS next Y71.33% ROA-39.48% Short Interest2.57M Perf Year-19.83%
Cash/sh1.02 P/C4.54 EPS next 5Y- ROE-84.68% 52W Range3.89 - 7.28 Perf YTD-29.01%
Dividend Est.- P/FCF- EPS past 5Y51.89% ROI-55.02% 52W High-36.13% Beta1.97
Dividend TTM- Quick Ratio2.10 Sales past 5Y44.97% Gross Margin74.96% 52W Low19.54% ATR (14)0.23
Dividend Ex-Date- Current Ratio2.10 EPS Y/Y TTM9.41% Oper. Margin-204.11% RSI (14)45.73 Volatility4.94% 4.43%
Employees69 Debt/Eq0.91 Sales Y/Y TTM198.84% Profit Margin-181.75% Recom1.00 Target Price17.40
Option/ShortYes / Yes LT Debt/Eq0.90 EPS Q/Q-16.55% Payout- Rel Volume0.56 Prev Close4.91
Sales Surprise-8.87% EPS Surprise14.29% Sales Q/Q18.96% EarningsMay 08 BMO Avg Volume214.57K Price4.65
SMA20-1.27% SMA50-2.05% SMA200-10.52% Trades Volume120,743 Change-5.30%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Reiterated Maxim Group Buy $12 → $18
Mar-12-24Initiated William Blair Outperform
Mar-17-23Initiated Maxim Group Buy $12
Jun-03-24 11:00AM
May-09-24 12:24PM
07:30AM
03:03AM
May-08-24 11:57AM
09:12AM Loading…
09:12AM
08:15AM
07:23AM
07:00AM
May-01-24 07:30AM
Apr-29-24 07:30AM
Apr-15-24 05:01PM
Apr-10-24 07:30AM
Apr-01-24 12:46PM
Mar-29-24 12:07PM
09:52PM Loading…
Mar-28-24 09:52PM
06:11PM
04:53PM
04:32PM
Mar-26-24 04:30PM
Mar-25-24 04:30PM
Mar-21-24 10:00AM
Mar-18-24 07:30AM
Mar-07-24 11:56AM
Mar-04-24 07:30AM
Feb-28-24 07:30AM
Feb-15-24 03:49AM
Feb-06-24 07:30AM
Jan-23-24 07:30AM
Jan-08-24 07:30AM
08:55AM Loading…
Jan-04-24 08:55AM
Dec-27-23 07:30AM
Nov-20-23 07:30AM
Nov-12-23 08:42AM
Nov-07-23 08:17AM
07:08AM
07:00AM
Oct-31-23 07:30AM
Oct-19-23 07:30AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Oct-02-23 07:30AM
Sep-20-23 07:30AM
Sep-09-23 08:00PM
Sep-05-23 07:30AM
Sep-04-23 09:55AM
Sep-01-23 07:31AM
Aug-31-23 12:13PM
07:30AM
Aug-19-23 07:40AM
Aug-17-23 09:55AM
Aug-15-23 12:15AM
Aug-14-23 07:42AM
07:30AM
Aug-07-23 04:45PM
Aug-02-23 07:30AM
Jul-19-23 10:30AM
07:30AM
Jun-20-23 07:30AM
Jun-13-23 07:30AM
Jun-03-23 07:30AM
May-16-23 06:22AM
May-15-23 05:55PM
04:59PM
04:05PM
May-10-23 07:30AM
May-09-23 07:30AM
May-08-23 07:30AM
May-03-23 07:30AM
Apr-17-23 04:05PM
06:18AM
Apr-04-23 07:30AM
Mar-30-23 07:30AM
Mar-17-23 07:30AM
Mar-15-23 07:26AM
Mar-07-23 07:00AM
Mar-06-23 07:30AM
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson ThomasDirectorSep 06 '23Buy4.8810,00048,76410,000Sep 06 04:39 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 06 '23Buy4.961,0004,95915,309Sep 06 05:11 PM
Bode John BDirectorSep 05 '23Buy5.1310,00051,33320,000Sep 06 04:40 PM
Schafer JoshuaCCO & EVP, Bus. DevelopmentSep 05 '23Buy5.135002,5643,500Sep 06 05:11 PM
Watton Corey MichaelDirectorJun 23 '23Buy5.952751,6361,000Jun 26 04:19 PM